Natco CEO On Dynamics In The HCV Market
Nexavar compulsory license holder Natco Pharma is counted among the leading players in the Indian oncology market and now looks to be aiming for an encore in the hepatitis C segment. Natco vice chair and CEO Rajeev Nannapaneni talks to Scrip of the large patient numbers on HCV therapy and outlines a potential market "split" in certain rest of the world (RoW) territories with the arrival of Gilead's Epclusa.
You may also be interested in...
Fixed-dose combo of sofosbuvir and velpatasvir is approved to treat genotypes 1-6 and be the first ribavirin-free regimen for genotypes 2 and 3 of the virus.
Two suppliers, multiple brands and a "super" competitive market. That sums up, at least for now, the current situation with respect to sofosbuvir generic versions that have been launched in India.
Patent challenger Natco Pharma has made a strategic about turn and has now emerged as a licensee for Gilead Sciences's blockbuster hepatitis C therapy, Sovaldi (sofosbuvir).